Back to Search

Obicetrapib for Preclinical Alzheimer's Disease

Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease

Recruiting Phase 2 Interventional Study
Preclinical Alzheimer's Disease
More trials: Alzheimer's clinical trials· Alzheimer's trials in Tennessee
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
55 – 85
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Prevention
Participants needed
400 (estimated)
Sponsor
NewAmsterdam Pharma · Industry
Who this trial is looking for

This trial is looking for adults who might be at risk for Preclinical Alzheimer's Disease. Participants will take a drug called Obicetrapib to see how it affects their condition.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have been diagnosed with preclinical Alzheimer's Disease

You may not be able to join if

  • My APOE genotype does not meet the study's requirements

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

A study evaluating Obicetrapib in adults potentially at risk for Preclinical Alzheimer's Disease

Trial Locations

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * participants with preclinical AD Exclusion Criteria: * APOE genotype not meeting protocol-defined eligibility criteria
Contacts

No contact information available.

NCT ID: NCT07794670 Source: ClinicalTrials.gov